GoldenGolden
Advanced Search
SpringWorks Therapeutics

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that takes a precision medicine approach in acquiring, developing and commercializing medicines for patient populations that are suffering from rare diseases and cancer.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that takes a precision medicine approach in acquiring, developing and commercializing medicines for patient populations that are suffering from rare diseases and cancer.

Its lead pipeline programs are in potentially registrational clinical trials for rare oncology indications. Nirogacestat, its gamma secretase inhibitor, is in a Phase 3 clinical trial for treating desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors.

Mirdametinib, its MEK inhibitor, is in a Phase 2b clinical trial for treating adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), which are peripheral nerve sheath tumors that cause severe pain, disfigurement and shortened life span.

SpringWorks is advancing, in partnership with industry leaders, several other programs addressing highly prevalent, genetically defined cancers, including evaluating nirogacestat as a cornerstone of BCMA combination therapy for patients with several myeloma and several efforts in RAS and RAF-mutated solid tumors with advanced precision medicine approaches for these types of cancer.

Timeline

April 2019
SpringWorks Therapeutics raises a $125,000,000 series B round from ArrowMark Partners, Biotechnology Value Fund, GlaxoSmithKline, HBM Healthcare Investments AG, Laurion Capital Management, LifeArc, OrbiMed, Samsara BioCapital, Surveyor Capital and Tavistock Group.
April 1, 2019
SpringWorks Therapeutics raises a $125,000,000 series B round from Perceptive Advisors.
September 2017
SpringWorks Therapeutics raises a $103,000,000 series A round from Bain Capital Double Impact, Bain Capital Life Sciences, LifeArc, OrbiMed and Pfizer.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
July 6, 2021
BioSpace
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here's a look.
Alex Keown
May 14, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
BioSpace
May 10, 2021
BioSpace
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development.
Krystle Vermes
May 29, 2020
BioSpace
The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
BioSpace
May 26, 2020
BioSpace
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Julie Hambleton, M.D. to the Company's Board of Directors.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.